{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:41:21Z","timestamp":1760762481574,"version":"build-2065373602"},"reference-count":30,"publisher":"Japanese Society of Internal Medicine","issue":"20","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2025,10,15]]},"DOI":"10.2169\/internalmedicine.5179-24","type":"journal-article","created":{"date-parts":[[2025,4,11]],"date-time":"2025-04-11T18:09:46Z","timestamp":1744394986000},"page":"2966-2970","source":"Crossref","is-referenced-by-count":0,"title":["Delayed Hepatitis B Virus Reactivation at 33 Months after the Completion of Rituximab-based Chemotherapy"],"prefix":"10.2169","volume":"64","author":[{"given":"Banri","family":"Ogawa","sequence":"first","affiliation":[{"name":"Department of Gastroenterology, Hitachi General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Kamoshida","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hitachi General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asaji","family":"Yamamoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hitachi General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Yamaguchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hitachi General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yukako","family":"Hamano","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hitachi General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haruka","family":"Okawara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hitachi General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Okawara","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hitachi General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobushige","family":"Kakinoki","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hitachi General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Hirai","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Hitachi General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Myint A, Tong MJ, Beaven SW. Reactivation of hepatitis B virus: a review of clinical guidelines. Clin Liver Dis 15: 162-167, 2020.","DOI":"10.1002\/cld.883"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Umemura T, Tanaka E, Kiyosawa K, et al. Mortality secondary to fulminant hepatic failure in patients with prior resolution of hepatitis B virus infection in Japan. Clin Infect Dis 47: e52-e56, 2008.","DOI":"10.1086\/590968"},{"key":"3","doi-asserted-by":"publisher","unstructured":"3. Reddy KR, Beavers KL, Hammond SP, et al.; American Gastroenterological Association Institute. American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148: 215-219, 2015.","DOI":"10.1053\/j.gastro.2014.10.039"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sarin SK, Kumar M, Lau GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 10: 1-98, 2016.","DOI":"10.1007\/s12072-015-9675-4"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 67: 370-398, 2017.","DOI":"10.1016\/j.jhep.2017.03.021"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Moretto F, Catherine FX, Esteve C, Blot M, Piroth L. Isolated anti-HBc: significance and management. J Clin Med 9: 202, 2020.","DOI":"10.3390\/jcm9010202"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Korean Association for the Study of the Liver (KASL). KASL clinical practice guidelines for management of chronic hepatitis B. Clin Mol Hepatol 25: 93-159, 2019.","DOI":"10.3350\/cmh.2019.1002"},{"key":"8","unstructured":"8. Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. The guidelines of prevention and treatment for chronic hepatitis B (2019 version). Zhonghua Gan Zang Bing Za Zhi 27: 938-961, 2019 (in Chinese)."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Lau G, Yu ML, Wong G, et al. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy. Hepatol Int 15: 1031-1048, 2021.","DOI":"10.1007\/s12072-021-10239-x"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hwang JP, Feld JJ, Hammond SP, et al. Hepatitis B virus screening and management for patients with cancer prior to therapy: ASCO provisional clinical opinion update. J Clin Oncol 38: 3698-3715, 2020.","DOI":"10.1200\/JCO.20.01757"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Haider M, Flocco G, Lopez R, et al. Retrospective observational study of temporal trends and outcomes of hepatitis B screening in patients receiving rituximab. BMJ Open 10: e043672, 2020.","DOI":"10.1136\/bmjopen-2020-043672"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Hwang JP, Barbo AG, Perrillo RP. Hepatitis B reactivation during cancer chemotherapy: an international survey of the membership of the American Association for the Study of Liver Diseases. J Viral Hepat 22: 346-352, 2015.","DOI":"10.1111\/jvh.12305"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Wi CI, Loo NM, Larson JJ, et al. Low level of hepatitis B virus screening among patients receiving chemotherapy. Clin Gastroenterol Hepatol 13: 970-975, 2015.","DOI":"10.1016\/j.cgh.2014.10.032"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Oketani M, Ido A, Uto H, et al. Prevention of hepatitis B virus reactivation in patients receiving immunosuppressive therapy or chemotherapy. Hepatol Res 42: 627-636, 2012.","DOI":"10.1111\/j.1872-034X.2012.00998.x"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Seto WK, Chan TS, Hwang YY, et al. Hepatitis B reactivation in patients with previous hepatitis B virus exposure undergoing rituximab-containing chemotherapy for lymphoma: a prospective study. J Clin Oncol 32: 3736-3743, 2014.","DOI":"10.1200\/JCO.2014.56.7081"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Tang Z, Li X, Wu S, et al. Risk of hepatitis B reactivation in HBsAg-negative\/HBcAb-positive patients with undetectable serum HBV DNA after treatment with rituximab for lymphoma: a meta-analysis. Hepatol Int 11: 429-433, 2017.","DOI":"10.1007\/s12072-017-9817-y"},{"key":"17","doi-asserted-by":"publisher","unstructured":"17. Tsai YF, Yang CI, Du JS, et al. Rituximab increases the risk of hepatitis B virus reactivation in non-Hodgkin lymphoma patients who are hepatitis B surface antigen-positive or have resolved hepatitis B virus infection in a real-world setting: a retrospective study. PeerJ 7: e7481, 2019.","DOI":"10.7717\/peerj.7481"},{"key":"18","doi-asserted-by":"publisher","unstructured":"18. Kusumoto S, Arcaini L, Hong X, et al. Risk of HBV reactivation in patients with B-cell lymphomas receiving obinutuzumab or rituximab immunochemotherapy. Blood 133: 137-146, 2019.","DOI":"10.1182\/blood-2018-04-848044"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Clerico M, Dogliotti I, Ghione P, et al. HBV reactivation in patients with past infection affected by non-Hodgkin lymphoma and treated with anti-CD20 antibody based immuno-chemotherapy: a multicenter experience. J Pers Med 12: 285, 2022.","DOI":"10.3390\/jpm12020285"},{"key":"20","doi-asserted-by":"publisher","unstructured":"20. Hui CK, Cheung WW, Zhang HY, et al. Kinetics and risk of de novo hepatitis B infection in HBsAg-negative patients undergoing cytotoxic chemotherapy. Gastroenterology 131: 59-68, 2006.","DOI":"10.1053\/j.gastro.2006.04.015"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Hsu C, Tsou HH, Lin SJ, et al. Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 59: 2092-3100, 2014.","DOI":"10.1002\/hep.26718"},{"key":"22","doi-asserted-by":"publisher","unstructured":"22. Loomba R, Liang TJ. Hepatitis B reactivation associated with immune suppressive and biological modifier therapies: current concepts, management strategies and future directions. Gastroenterology 152: 1297-1309, 2017.","DOI":"10.1053\/j.gastro.2017.02.009"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Hayashi M, Abe K, Fujita M, et al. Hepatitis B virus reactivation in a patient with nonalcoholic steatohepatitis 41 months after rituximab-containing chemotherapy. Intern Med 58: 375-380, 2019.","DOI":"10.2169\/internalmedicine.1587-18"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Kusumoto S, Tanaka Y, Mizokami M, et al. Reactivation of hepatitis B virus following systemic chemotherapy for malignant lymphoma. Int J Hematol 90: 13-23, 2009.","DOI":"10.1007\/s12185-009-0359-5"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Tsutsumi Y, Yamamoto Y, Ito S, et al. Hepatitis B virus reactivation with a rituximab-containing regimen. World J Hepatol 7: 2344-2351, 2015.","DOI":"10.4254\/wjh.v7.i21.2344"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Kusumoto S, Tanaka Y, Suzuki R, et al. Monitoring of hepatitis B virus (HBV) DNA and risk of HBV reactivation in B-cell lymphoma: a prospective observational study. Clin Infect Dis 61: 719-729, 2015.","DOI":"10.1093\/cid\/civ344"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Iijima K. Rituximab for childhood refractory nephrotic syndrome. Pediatr Int 53: 617-621, 2011.","DOI":"10.1111\/j.1442-200X.2011.03432.x"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Garcia-Rodriguez MJ, Canales MA, Hernandez-Maraver D, et al. Late reactivation of resolved hepatitis B virus infection: an increasing complication post rituximab-based regimens treatment?. Am J Hematol 83: 673-675, 2008.","DOI":"10.1002\/ajh.21214"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Zoppoli G, Bruzzone B, Caligiuri P, et al. From a medical mistake to a clinical warning: the case of HBV mutant virus reactivation in haematological patients. Br J Haematol 144: 969-970, 2009.","DOI":"10.1111\/j.1365-2141.2008.07539.x"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Yeo W, Chan TC, Leung NW, et al. Hepatitis B virus reactivation in lymphoma patients with prior resolved hepatitis B undergoing anticancer therapy with or without rituximab. J Clin Oncol 27: 605-611, 2009.","DOI":"10.1200\/JCO.2008.18.0182"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5179-24\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T04:27:22Z","timestamp":1760761642000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/64\/20\/64_5179-24\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":30,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.5179-24","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"type":"print","value":"0918-2918"},{"type":"electronic","value":"1349-7235"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"article-number":"5179-24"}}